Ubs Group Ag Novavax Inc Call Options Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 09, 2024	BUY	$4.8 - $7.67 $576,000 - $920,400	120,000 Added 240.0%	170,000 $816,000
Q2 2023 Aug 11, 2023	BUY	$6.67 - $9.52 $333,500 - $476,000	50,000 New	50,000 $371,000
Q4 2022 Feb 08, 2023	SELL	$8.86 - $25.04 $59,361 - $167,768	-6,700 Reduced 27.92%	17,300 $177,000
Q3 2022 Nov 10, 2022	BUY	$18.2 - $76.12 $436,800 - $1.83 Million	24,000 New	24,000 $437,000
Q1 2021 May 12, 2021	BUY	$112.98 - $319.93 $11,298 - $31,993	100 New	100 $18,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.